Rotator Cuff TearsNCT07781553
Biomarkers to Predict Rotator Cuff Repair Healing on Postoperative MRI
A study testing MRN in people with Rotator Cuff Tears, run by Joseph W. Galvin at 1 site in United States.
Trial summary
Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Rotator Cuff Tears
- What is being tested?
- MRN
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 30 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 18-99 years partial or full thickness posterior superior rotator cuff tear that underwent surgical repair and are consented in the Orthopedics Biobank under IRB# 202403832.
- Exclusion criteria prisoners pregnant patients patients with prior shoulder surgery on the ipsilateral side adhesive capsulitis patients undergoing concomitant distal clavicle resection worker's compensation patients with postoperative complications.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Iowa
Iowa City, Iowa, 52242
Joseph Galvin, DO, 3193537091, joseph-galvin@uiowa.edu
Maria F Bozoghlian, MD, 3196785003, maria-bozoghlian@uiowa.edu
About this study
Official title: Biomarkers to Predict Rotator Cuff Repair Healing
Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. The purpose of this study is to perform diagnostic imaging study (MRI without contrast), for research purposes, to subjects in the Orthopedics Biobank (IRB#202403832), to identify biomarkers associated with failure of rotator cuff repair healing. We will evaluate biomarkers in synovial fluid and shoulder tissues collected and analyzed as part of the IRB#202403832, and correlate the difference in biomarkers in patients that did and did not have signs of healing in the MRI. Secondarily, we aim to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery.
This will be a study from a population of patients who are enrolled in the Orthopedic biorepository under IRB #202403832.
Patients who underwent a rotator cuff repair will be invited to get an MRI without contrast of their operated shoulder at a period between 6 months to 1 year post-operative.
Read the detailed description
Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94% [11-15]. A number of variables have been identified which influence rotator cuff repair healing rates including: older age (> 70 years old), size of the tear in anterior posterior dimension, level of tendon retraction, muscle quality and fatty infiltration, osteoporosis, smoking, family history of rotator cuff tears, diagnosis of diabetes mellitus, and level of work activity [7,16-26]. However, there is a paucity of literature and investigation into biomarkers significantly associated with rotator cuff repair healing rates. Tashjian et al. investigated 72 patients undergoing arthroscopic rotator cuff repair for a full-thickness posterosuperior tear. Magnetic resonance imaging studies were performed at a minimum of 1 year postoperatively. The authors found that 42% of repairs failed to heal. Multivariate regression analysis showed a significant association between a family history of rotator cuff tears and overall healing failure (P = .036). Additionally, they identified an increased risk for the presence of a rare allele for SNP rs17583842 single-nucleotide polymorphism (SNP) in the estrogen-related receptor beta (ESRRB) gene. This is the first genetic biomarker to be identified as significantly associated with repair healing. Additional authors have evaluated transcriptomics and gene expression differences in rotator cuff tissue collected during surgery between patients who had good outcomes versus those who had a retear. They found that patients who had poor healing outcomes showed greater expression of gene sets related to extracellular matrix production (P < .0001) and cellular biosynthetic pathways (P < .001), while patients who had good healing outcomes showed greater expression of genes associated with the proinflammatory (M1) macrophage phenotype (P < .05). Although this data is interesting, tissue level biomarkers are less useful in the clinical setting as a preoperative prognostic tool. No studies to our knowledge have identified blood transcriptomic or proteomic biomarkers associated with rotator cuff tear healing.
Therefore, we aim to investigate this through this protocol. Numerous studies have identified that the diagnosis of diabetes mellitus type 2 (DM2) is a risk factor for failure of rotator cuff repair healing [28]. Yang et al. conducted a meta-analysis to compare clinical outcomes and retear rates after rotator cuff repair in patients with and without diabetes. Diabetes was associated with a higher retear rate (19.3% in patients without diabetes vs 28.2% in patients with diabetes; P < .0001). The retear rate according to the severity of sustained hyperglycemia in the subgroup analysis was 14.6% in patients without diabetes, versus 22.7% in patients with well-controlled diabetes (<7.0% of preoperative serum HbA1c level; P = .12) and 40% in patients with uncontrolled diabetes (HbA1c level >7.0%; P < .00001). Recently, studies have identified that serum fructosamine, rather than Hemoglobin A1C percentage, is a more accurate marker of acute glycemic control. Shohat et al. evaluated 1119 patients undergoing total knee arthroplasty. They found that patients with high fructosamine (> 293) were 11.2 times more likely to develop prosthetic joint infection compared with patients with low fructosamine (p = 0.001). Another study published in the prestigious Nature Journal by Shohat et al. assessed the utility of serum fructosamine to predict adverse outcomes following total hip arthroplasty (THA) [30]. Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). We hypothesize that fructosamine level is significantly associated with healing rates following rotator cuff repair and plan to investigate this in a prospective fashion through this protocol.
One of the aims of this study protocol is to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery. Kwon et al. conducted a case-control study of 603 patients who underwent arthroscopic rotator cuff repair and had 1-year follow up with a postoperative MRI. Of the 603 patients, the healing rate was 24%. The following independent risk factors were identified in the multivariate analysis: age > 70 years at the time of surgery (P = .003, Odds Ratio (OR) = 2.71), size of the tear in anterior posterior dimension (P = .033, OR = 1.94), level of tendon retraction (P = .000, OR = 4.56), fatty infiltration of infraspinatus exceeding grade 2 (P = .001, OR = 2.91), low bone mineral density as measured on DEXA scans (T score > -2.5, P = .04, OR = 1.95), and high level of work activity (P = .036, OR = 2.18). They created a 15-point scoring system comprised the following: 4 points for retraction; 3 points for fatty infiltration of infraspinatus; and 2 points for anteroposterior tear size, age, bone mineral density, and work activity. These variables were weighted according to multivariate analysis ORs. Patients with less than or equal to 4 points had a 6.0% healing failure rate, and those with greater than or equal to 5 and greater than or equal to 10 points had 55.2% and 86.2% healing failure rates, respectively. This Rotator Cuff Healing Index (ROHI) score is clinically helpful as it can provide preoperative prognostic information to the surgeon and patient to guide decision making on whether to perform an arthroscopic repair, perform a repair with possible patch augmentation, or potentially guide the decision making to a reverse shoulder arthroplasty. Through this study protocol, we aim to identify current accepted protein biomarkers (fructosamine) and perform discovery proteomics and transcriptomics to identify novel biomarkers associated with rotator cuff repair healing.
- Conditions
- Rotator Cuff Tears
- Being tested
- MRN
- Keywords
- rotator cuff tear; rotator cuff healing
- Medical subject headings
- Rotator Cuff Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRNDiagnostic test
MRN without contrast
| Study group | Role | What they receive |
|---|---|---|
| Rotator cuff repair | Other | All participants of the Orthopedics Biobank who underwent a rotator cuff repair will be part of arm 1 Receives: Diagnostic Test: MRN |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rotator cuff healing
Rotator cuff healing postoperatively, as assessed on MRI
Measured: 6 months to 1 year post-operative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Jul 2027 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rotator Cuff TearsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Joseph W. Galvin
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Joseph W. Galvin, University of Iowa
- Investigators
- Joseph Galvin, MD, Principal investigator, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07781553
- Sponsor's protocol ID
- 202406235
- Status last verified
- Aug 2026
- First submitted
- 18 Aug 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biomarkers to Predict Rotator Cuff Repair Healing
- ClinicalTrials.gov ID
- NCT07781553
- Acronym / sponsor ID
- 202406235
- Conditions
- Rotator Cuff Tears
- Keywords
- rotator cuff tear; rotator cuff healing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Joseph W. GalvinUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Jul 2027 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 24 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. The purpose of this study is to perform diagnostic imaging study (MRI without contrast), for research purposes, to subjects in the Orthopedics Biobank (IRB#202403832), to identify biomarkers associated with failure of rotator cuff repair healing. We will evaluate biomarkers in synovial fluid and shoulder tissues collected and analyzed as part of the IRB#202403832, and correlate the difference in biomarkers in patients that did and did not have signs of healing in the MRI. Secondarily, we aim to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery.
This will be a study from a population of patients who are enrolled in the Orthopedic biorepository under IRB #202403832.
Patients who underwent a rotator cuff repair will be invited to get an MRI without contrast of their operated shoulder at a period between 6 months to 1 year post-operative.
Detailed description
Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94% [11-15]. A number of variables have been identified which influence rotator cuff repair healing rates including: older age (> 70 years old), size of the tear in anterior posterior dimension, level of tendon retraction, muscle quality and fatty infiltration, osteoporosis, smoking, family history of rotator cuff tears, diagnosis of diabetes mellitus, and level of work activity [7,16-26]. However, there is a paucity of literature and investigation into biomarkers significantly associated with rotator cuff repair healing rates. Tashjian et al. investigated 72 patients undergoing arthroscopic rotator cuff repair for a full-thickness posterosuperior tear. Magnetic resonance imaging studies were performed at a minimum of 1 year postoperatively. The authors found that 42% of repairs failed to heal. Multivariate regression analysis showed a significant association between a family history of rotator cuff tears and overall healing failure (P = .036). Additionally, they identified an increased risk for the presence of a rare allele for SNP rs17583842 single-nucleotide polymorphism (SNP) in the estrogen-related receptor beta (ESRRB) gene. This is the first genetic biomarker to be identified as significantly associated with repair healing. Additional authors have evaluated transcriptomics and gene expression differences in rotator cuff tissue collected during surgery between patients who had good outcomes versus those who had a retear. They found that patients who had poor healing outcomes showed greater expression of gene sets related to extracellular matrix production (P < .0001) and cellular biosynthetic pathways (P < .001), while patients who had good healing outcomes showed greater expression of genes associated with the proinflammatory (M1) macrophage phenotype (P < .05). Although this data is interesting, tissue level biomarkers are less useful in the clinical setting as a preoperative prognostic tool. No studies to our knowledge have identified blood transcriptomic or proteomic biomarkers associated with rotator cuff tear healing.
Therefore, we aim to investigate this through this protocol. Numerous studies have identified that the diagnosis of diabetes mellitus type 2 (DM2) is a risk factor for failure of rotator cuff repair healing [28]. Yang et al. conducted a meta-analysis to compare clinical outcomes and retear rates after rotator cuff repair in patients with and without diabetes. Diabetes was associated with a higher retear rate (19.3% in patients without diabetes vs 28.2% in patients with diabetes; P < .0001). The retear rate according to the severity of sustained hyperglycemia in the subgroup analysis was 14.6% in patients without diabetes, versus 22.7% in patients with well-controlled diabetes (<7.0% of preoperative serum HbA1c level; P = .12) and 40% in patients with uncontrolled diabetes (HbA1c level >7.0%; P < .00001). Recently, studies have identified that serum fructosamine, rather than Hemoglobin A1C percentage, is a more accurate marker of acute glycemic control. Shohat et al. evaluated 1119 patients undergoing total knee arthroplasty. They found that patients with high fructosamine (> 293) were 11.2 times more likely to develop prosthetic joint infection compared with patients with low fructosamine (p = 0.001). Another study published in the prestigious Nature Journal by Shohat et al. assessed the utility of serum fructosamine to predict adverse outcomes following total hip arthroplasty (THA) [30]. Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). We hypothesize that fructosamine level is significantly associated with healing rates following rotator cuff repair and plan to investigate this in a prospective fashion through this protocol.
One of the aims of this study protocol is to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery. Kwon et al. conducted a case-control study of 603 patients who underwent arthroscopic rotator cuff repair and had 1-year follow up with a postoperative MRI. Of the 603 patients, the healing rate was 24%. The following independent risk factors were identified in the multivariate analysis: age > 70 years at the time of surgery (P = .003, Odds Ratio (OR) = 2.71), size of the tear in anterior posterior dimension (P = .033, OR = 1.94), level of tendon retraction (P = .000, OR = 4.56), fatty infiltration of infraspinatus exceeding grade 2 (P = .001, OR = 2.91), low bone mineral density as measured on DEXA scans (T score > -2.5, P = .04, OR = 1.95), and high level of work activity (P = .036, OR = 2.18). They created a 15-point scoring system comprised the following: 4 points for retraction; 3 points for fatty infiltration of infraspinatus; and 2 points for anteroposterior tear size, age, bone mineral density, and work activity. These variables were weighted according to multivariate analysis ORs. Patients with less than or equal to 4 points had a 6.0% healing failure rate, and those with greater than or equal to 5 and greater than or equal to 10 points had 55.2% and 86.2% healing failure rates, respectively. This Rotator Cuff Healing Index (ROHI) score is clinically helpful as it can provide preoperative prognostic information to the surgeon and patient to guide decision making on whether to perform an arthroscopic repair, perform a repair with possible patch augmentation, or potentially guide the decision making to a reverse shoulder arthroplasty. Through this study protocol, we aim to identify current accepted protein biomarkers (fructosamine) and perform discovery proteomics and transcriptomics to identify novel biomarkers associated with rotator cuff repair healing.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Rotator cuff repair | Other | Diagnostic Test: MRNAll participants of the Orthopedics Biobank who underwent a rotator cuff repair will be part of arm 1 |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- age 18-99 years partial or full thickness posterior superior rotator cuff tear that underwent surgical repair and are consented in the Orthopedics Biobank under IRB# 202403832.
- Exclusion criteria prisoners pregnant patients patients with prior shoulder surgery on the ipsilateral side adhesive capsulitis patients undergoing concomitant distal clavicle resection worker's compensation patients with postoperative complications.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRNMRN without contrast | Diagnostic test | Rotator cuff repair |
Primary outcome
Rotator cuff healing
Time frame: 6 months to 1 year post-operative
Rotator cuff healing postoperatively, as assessed on MRI
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
Related trials for Rotator Cuff Tears
Active, not recruitingPhase 1
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults
Rotator Cuff Tears, Muscle Atrophy or Weakness
Not yet recruiting
Voll Non-Degradable Shoulder Spacer FIH Study
Massive Rotator Cuff Tears, Massive Rotator Cuff Tear
Active, not recruitingPhase 2
Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder
Orthopedics, Traumatology
Recruiting
SMR Stemless Reverse vs SMR Reverse Shoulder System
Arthroplasty, Replacement
Active, not recruiting
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Rotator Cuff Tears
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joseph Galvin, MD principal investigator
University of Iowa
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRN in people with Rotator Cuff Tears, run by Joseph W. Galvin at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joseph Galvin, Other, MD (3193848378, joseph-galvin@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rotator cuff healing (time frame: 6 months to 1 year post-operative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.